Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Coronary Heart Disease and Stent Use
  • Coronary Heart Disease
  • Treatment for Coronary Heart Disease
  • The Use of Cardiac Stents
• The Drug-Eluting Stent Market
  • Market Leaders
  • The Battle for Guidant
• Concerns Arise over Drug-Eluting Stents
• Emerging Innovations in Drug-Eluting Stents
  • Medtronic' s Endeavor Stent
  • Abbott' s Xience/Boston Scientifi c' s Promus
  • Conor Medsystems' Costar
  • Biosensors' BioMatrix
• The Outlook for the Drug-Eluting Stent Market
  • Safety Concerns Create Commercial Opportunities
  • The Emergence of Competitive Pricing
  • Bioabsorbable Stents
  • Market Rebound

Tables

• 1. Prevalence of Coronary Heart Disease and Acute Coronary Syndrome, 2006
• 2. Emerging Drug-Eluting Stents

Figures

• 1. Milestones in the Drug-Eluting Stent Market
• 2. Stent Implantation, Restenosis, and Thrombosis
• 3. Worldwide Sales of Taxus Versus Cypher